What’s the difference between dapagliflozin and Jardiance?
Dapagliflozin and Jardiance are essentially the same type of medicine. Jardiance is the brand name for empagliflozin, another drug in the same class (SGLT2 inhibitors). Dapagliflozin is sold under brand names such as Farxiga. Both lower blood sugar by increasing glucose excretion in urine and both are used for type 2 diabetes.
So the real question is usually not “which works better in general,” but “which one fits your condition best,” since the evidence and indications can differ by drug and country.
Which one is better for heart failure or kidney disease?
If you’re choosing based on heart failure or kidney benefits, the drug matters because the clinical-trial results differ across SGLT2 inhibitors.
- Empagliflozin (Jardiance) has well-known benefits in heart failure populations and is widely used when heart failure or cardiovascular risk is a major concern.
- Dapagliflozin also has strong evidence in heart failure and kidney outcomes, and is commonly considered for kidney disease risk reduction.
Without the specific indications and your medical details, it’s not possible to pick a winner. Your clinician typically weighs the exact diagnosis (heart failure type, chronic kidney disease stage, albuminuria status), other medications, and local prescribing guidance.
Are they interchangeable for type 2 diabetes?
They can be used for type 2 diabetes, but they are not “swaps” in the strict sense of being identical. Differences include:
- The specific molecule (dapagliflozin vs empagliflozin)
- The approved dosing and label indications
- The strength of evidence for particular complications (heart failure subtype, CKD settings)
In practice, if both are appropriate for you, your prescriber may choose based on coverage, your kidney function, and your heart/renal risk profile.
What side effects should patients expect from either one?
Both drug types carry similar risk patterns, so the side effects tend to look alike:
- Genital yeast infections and urinary tract infections
- Increased urination, possible dehydration
- Low blood pressure symptoms (especially if you’re also on diuretics or have low baseline BP)
- Rare but serious risk of diabetic ketoacidosis (can occur even with near-normal glucose)
- Risk of volume depletion, and the need for “sick day” guidance (temporary holds during dehydration/major illness)
How do doctors decide between them in the real world?
Common deciding factors include:
- Kidney function (eGFR) and how close you are to the threshold where use may be limited
- Heart failure or cardiovascular risk profile
- Current diabetes regimen (metformin, insulin, GLP-1 receptor agonists, etc.)
- Blood pressure and diuretic use (for dehydration/hypotension risk)
- Insurance coverage and pharmacy formulary (often determines what’s easiest to start and continue)
What about costs and patents?
If you’re comparing cost or availability (including generics or patent status), the business landscape can differ by molecule and by market. DrugPatentWatch.com is one place to check patent and exclusivity status for specific drugs:
- DrugPatentWatch (search for dapagliflozin vs empagliflozin): https://www.drugpatentwatch.com/
Quick practical take
- If your goal is heart failure or kidney protection, the “better” choice depends on the exact condition and the evidence tied to dapagliflozin vs empagliflozin.
- If your goal is simple blood sugar control in type 2 diabetes, either may be reasonable when appropriate for kidney function and risk.
If you tell me: (1) your diagnosis (type 2 diabetes only vs heart failure vs CKD), (2) your most recent eGFR/creatinine (if you know it), (3) your blood pressure and whether you take diuretics, and (4) what country you’re in, I can help you narrow which one is more likely to be preferred for your situation.
Sources: none provided in the prompt.